SYNTHESIS AND ANTIULCER ACTIVITY OF NOVEL 5-(2-ETHENYL SUBSTITUTED)-3(2H)-FURANONES

被引:46
作者
FELMAN, SW [1 ]
JIRKOVSKY, I [1 ]
MEMOLI, KA [1 ]
BORELLA, L [1 ]
WELLS, C [1 ]
RUSSELL, J [1 ]
WARD, J [1 ]
机构
[1] WYETH AYERST RES, DEPT EXPTL THERAPEUT, PRINCETON, NJ 08543 USA
关键词
D O I
10.1021/jm00085a003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In order to investigate new antiulcer agents, spizofurone 1 (AG-629) was fragmented and reassembled to generate 5-phenyl-2,2-dimethyl-3(2H)-furanone (bullatenone, 2). Because of the antiulcer activity of 2,5-phenyl-substituted 2,2-dimethyl-3(2H)-furanones (3-6) were made and shown to have poor activity. Insertion of an ethenyl link between the furanone and phenyl rings gave 5-(2-phenylethenyl)-2,2-dimethyl-3(2H)-furanone (7). This compound had better activity than 2. Compounds 8-41 were synthesized to evaluate the SAR in 5-(2-ethenyl substituted)-3(2H)-furanones. Electron-withdrawing substituents on the aromatic ring (8, 10, 19, and 20) gave 2-3-fold higher activity. Further increases in the activity were found when the phenyl ring was replaced by heterocyclic nuclei. Compounds that contained a thiophene (29), pyridine (24-26), or quinoline ring (32) had the best activity. Replacement of the methyl group on the furanone ring with a phenyl (34) or p-fluorophenyl (40) substituent in the 2-pyridine series gave compounds with activity that ranked with the best obtained in this study. The best compounds from the above SAR studies were evaluated in the ethanol-necrosis model for duration of cytoprotection action. Compounds 19, 24, and 29, which had the best duration of action, were tested with AG-629 in the acidified aspirin and indomethacin-induced lesion models. Only compound 24 had equivalent activity with AG-629 in both models.
引用
收藏
页码:1183 / 1190
页数:8
相关论文
共 29 条
[1]  
CHAUDHURY TK, 1978, GASTROENTEROLOGY, V74, P58
[2]   O-CARBAMOYLOXIMES [J].
DALTON, DR ;
FOLEY, HG .
JOURNAL OF ORGANIC CHEMISTRY, 1973, 38 (24) :4200-4203
[3]  
DIJOSEPH J, UNPUB
[4]   ASSESSMENT OF THE MUCUS-BICARBONATE BARRIER IN THE STOMACH OF PATIENTS WITH CHRONIC GASTRIC DISORDERS [J].
GUSLANDI, M ;
BALLARIN, E .
CLINICA CHIMICA ACTA, 1984, 144 (2-3) :133-136
[5]  
HORNEREMMONS, 1987, CHEM LETT, P323
[6]  
INATOMI N, 1985, ARZNEIMITTELFORSCH, V35-2, P1553
[7]   SPIZOFURONE (AG-629) INCREASES GASTRIC-MUCOSAL BLOOD-FLOW IN DOGS - A POSSIBLE MECHANISM OF ITS ANTI-ULCER EFFECT [J].
INATOMI, N ;
SATOH, H ;
NAGAYA, H ;
MAKI, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 110 (03) :343-350
[8]   GASTRIC-MUCOSAL PROTECTION BY SPIZOFURONE [J].
INATOMI, N ;
SATOH, H ;
INADA, I ;
HIRATA, T ;
NAGAYA, H ;
MAKI, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 112 (01) :81-87
[9]   PARTIAL REDUCTION OF CARBOXYLIC-ACIDS TO ALDEHYDES VIA 3-ACYLTHIAZOLIDINE-2-THIONES WITH DIISOBUTYLALUMINUM HYDRIDE AND WITH LITHIUM TRI-TERT-BUTOXYALUMINUM HYDRIDE [J].
IZAWA, T ;
MUKAIYAMA, T .
BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 1979, 52 (02) :555-558
[10]   SYNTHESIS AND CONFIGURATIONAL ASSIGNMENT OF GEIPARVARIN - A NOVEL ANTI-TUMOR AGENT [J].
JERRIS, PJ ;
SMITH, AB .
JOURNAL OF ORGANIC CHEMISTRY, 1981, 46 (03) :577-585